{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T04:14:30Z","timestamp":1777176870769,"version":"3.51.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T00:00:00Z","timestamp":1590796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T00:00:00Z","timestamp":1590796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Purpose<\/jats:title>\n<jats:p>Efficacy of treosulfan, used in the treatment of marrow disorders, depends on the activity of its monoepoxy\u2014(EBDM) and diepoxy compounds. The study aimed to describe the pharmacokinetics of treosulfan and EBDM in the rat plasma and brain by means of mixed-effects modelling.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>The study had a one-animal-per-sample design and included ninty-six 10-week-old Wistar rats of both sexes. Treosulfan and EBDM concentrations in the brain and plasma were measured by an HPLC\u2013MS\/MS method. The population pharmacokinetic model was established in NONMEM software with a first-order estimation method with interaction.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>One-compartment pharmacokinetic model best described changes in the concentrations of treosulfan in plasma, and EBDM concentrations in plasma and in the brain. Treosulfan concentrations in the brain followed a two-compartment model. Both treosulfan and EBDM poorly penetrated the blood\u2013brain barrier (ratio of influx and efflux clearances through the blood\u2013brain barrier was 0.120 and 0.317 for treosulfan and EBDM, respectively). Treosulfan plasma clearance was significantly lower in male rats than in females (0.273\u00a0L\/h\/kg vs 0.419\u00a0L\/h\/kg).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The developed population pharmacokinetic model is the first that allows the prediction of treosulfan and EBDM concentrations in rat plasma and brain. These results provide directions for future studies on treosulfan regarding the contribution of transport proteins or the development of a physiological-based model.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s43440-020-00115-0","type":"journal-article","created":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T20:02:33Z","timestamp":1590868953000},"page":"1297-1309","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Population pharmacokinetic approach for evaluation of treosulfan and its active monoepoxide disposition in plasma and brain on the basis of a rat model"],"prefix":"10.1007","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5807-1109","authenticated-orcid":false,"given":"Dorota","family":"Danielak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micha\u0142","family":"Roma\u0144ski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Kasprzyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Artur","family":"Te\u017cyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franciszek","family":"G\u0142\u00f3wka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,30]]},"reference":[{"key":"115_CR1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1021\/tx0342058","volume":"17","author":"S Park","year":"2004","unstructured":"Park S, Tretyakova N. Structural characterization of the major DNA-DNA cross-link of 1,2,3,4-diepoxybutane. Chem Res Toxicol. 2004;17:129\u201336.","journal-title":"Chem Res Toxicol"},{"key":"115_CR2","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1016\/j.xphs.2018.06.019","volume":"107","author":"M Roma\u0144ski","year":"2018","unstructured":"Roma\u0144ski M, Girreser U, Te\u017cyk A, G\u0142\u00f3wka FK. N-7-guanine adduct of the active monoepoxide of prodrug treosulfan: first synthesis, characterization, and decomposition profile under physiological conditions. J Pharm Sci. 2018;107:2927\u201337.","journal-title":"J Pharm Sci"},{"key":"115_CR3","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.bbmt.2017.12.776","volume":"24","author":"A Shimoni","year":"2018","unstructured":"Shimoni A, Labopin M, Savani B, Hamladji R-M, Beelen D, Mufti G, et al. Intravenous busulfan compared with treosulfan-based conditioning for allogeneic stem cell transplantation in acute myeloid leukemia: a study on behalf of the acute leukemia working party of european society for blood and marrow transplantation. Biol Blood Marrow Transplant. 2018;24:751\u20137.","journal-title":"Biol Blood Marrow Transplant"},{"key":"115_CR4","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1182\/blood-2016-03-704015","volume":"128","author":"B Morillo-Gutierrez","year":"2016","unstructured":"Morillo-Gutierrez B, Beier R, Rao K, Burroughs L, Schulz A, Ewins A-M, et al. Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience. Blood. 2016;128:440\u20138.","journal-title":"Blood"},{"key":"115_CR5","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/j.bbmt.2017.06.002","volume":"23","author":"LM Burroughs","year":"2017","unstructured":"Burroughs LM, Shimamura A, Talano J-A, Domm JA, Baker KK, Delaney C, et al. Allogeneic hematopoietic cell transplantation using treosulfan-based conditioning for treatment of marrow failure disorders. Biol Blood Marrow Transplant. 2017;23:1669\u2013777.","journal-title":"Biol Blood Marrow Transplant"},{"key":"115_CR6","unstructured":"Beelen D, Trenschel R, Markiewicz M, Dzierzak-Mietla M, Groth C, Masszi T, et al. Results of a randomised phase-III-trial comparing treosulfan\/fludarabine to reduced-intensity conditioning with busulfan\/fludarabine before allogeneic haematopoietic stem-cell transplantation in acute myeloid leukaemia or myelodysplastic syndrome patients. Lisbon, Portugal. 2018. https:\/\/ebmt2018.org."},{"key":"115_CR7","unstructured":"European Medicines Agency. Trecondi [Internet]. Eur. Med. Agency. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/trecondi (2018). Accessd 17 Feb 2020."},{"key":"115_CR8","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ejps.2017.09.011","volume":"109","author":"M Roma\u0144ski","year":"2017","unstructured":"Roma\u0144ski M, Kasprzyk A, Walczak M, Zi\u00f3\u0142kowska A, G\u0142\u00f3wka F. Disposition of treosulfan and its active monoepoxide in a bone marrow, liver, lungs, brain, and muscle: studies in a rat model with clinical relevance. Eur J Pharm Sci. 2017;109:616\u201323.","journal-title":"Eur J Pharm Sci"},{"key":"115_CR9","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/sj.bmt.1702116","volume":"25","author":"S Seo","year":"2000","unstructured":"Seo S, Kami M, Honda H, Kashima T, Matsumura T, Moriya A, et al. Extramedullary relapse in the so-called \u2018sanctuary\u2019 sites for chemotherapy after donor lymphocyte infusion. Bone Marrow Transplant. 2000;25:226\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"115_CR10","doi-asserted-by":"crossref","first-page":"530356","DOI":"10.1155\/2013\/530356","volume":"2013","author":"AM Palmer","year":"2013","unstructured":"Palmer AM. Multiple sclerosis and the blood-central nervous system barrier. Cardiovasc Psychiatry Neurol. 2013;2013:530356.","journal-title":"Cardiovasc Psychiatry Neurol"},{"key":"115_CR11","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/sj.bmt.1704223","volume":"32","author":"K-H Lee","year":"2003","unstructured":"Lee K-H, Lee J-H, Choi S-J, Lee J-H, Kim S, Seol M, et al. Bone marrow vs extramedullary relapse of acute leukemia after allogeneic hematopoietic cell transplantation: risk factors and clinical course. Bone Marrow Transplant. 2003;32:835\u201342.","journal-title":"Bone Marrow Transplant"},{"key":"115_CR12","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/10428190902755513","volume":"50","author":"S Ocheni","year":"2009","unstructured":"Ocheni S, Iwanski GB, Schafhausen P, Zander AR, Ayuk F, Klyuchnikov E, et al. Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation. Leuk Lymphoma. 2009;50:551\u20138.","journal-title":"Leuk Lymphoma"},{"key":"115_CR13","first-page":"e1711","volume":"26","author":"JY Kim","year":"2016","unstructured":"Kim JY, Im SA, Lee JH, Lee JW, Chung NG, Cho B. Extramedullary relapse of acute myeloid and lymphoid leukemia in children: a retrospective analysis. Iran J Pediatr. 2016;26:e1711.","journal-title":"Iran J Pediatr"},{"key":"115_CR14","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jpba.2017.03.023","volume":"140","author":"M Roma\u0144ski","year":"2017","unstructured":"Roma\u0144ski M, Kasprzyk A, Te\u017cyk A, Widerowska A, \u017baba C, G\u0142\u00f3wka F. Determination of prodrug treosulfan and its biologically active monoepoxide in rat plasma, liver, lungs, kidneys, muscle, and brain by HPLC-ESI-MS\/MS method. J Pharm Biomed Anal. 2017;140:122\u20139.","journal-title":"J Pharm Biomed Anal"},{"key":"115_CR15","first-page":"34","volume":"51","author":"GR DiResta","year":"1990","unstructured":"DiResta GR, Lee J, Lau N, Ali F, Galicich JH, Arbit E. Measurement of brain tissue density using pycnometry. Acta Neurochir Suppl. 1990;51:34\u20136.","journal-title":"Acta Neurochir Suppl"},{"key":"115_CR16","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1124\/dmd.115.066050","volume":"43","author":"M Roma\u0144ski","year":"2015","unstructured":"Roma\u0144ski M, Baumgart J, B\u00f6hm S, G\u0142\u00f3wka FK. Penetration of treosulfan and its active monoepoxide transformation product into central nervous system of juvenile and young adult rats. Drug Metab Dispos. 2015;43:1946\u201354.","journal-title":"Drug Metab Dispos"},{"key":"115_CR17","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","volume":"79","author":"L Lindbom","year":"2005","unstructured":"Lindbom L, Pihlgren P, Jonsson EN, Jonsson N. PsN-toolkit\u2013a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79:241\u201357.","journal-title":"Comput Methods Programs Biomed"},{"key":"115_CR18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","volume":"75","author":"L Lindbom","year":"2004","unstructured":"Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN)\u2013a Perl module for NONMEM related programming. Comput Methods Programs Biomed. 2004;75:85\u201394.","journal-title":"Comput Methods Programs Biomed"},{"key":"115_CR19","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1038\/psp.2013.24","volume":"2","author":"RJ Keizer","year":"2013","unstructured":"Keizer RJ, Karlsson MO, Hooker A. Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose. CPT Pharmacomet Syst Pharmacol. 2013;2:e50.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"115_CR20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/10543409708835177","volume":"7","author":"LF Lacey","year":"1997","unstructured":"Lacey LF, Keene ON, Pritchard JF, Bye A. Common noncompartmental pharmacokinetic variables: are they normally or log-normally distributed? J Biopharm Stat. 1997;7:171\u20138.","journal-title":"J Biopharm Stat"},{"key":"115_CR21","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/BF02353461","volume":"23","author":"EI Ette","year":"1995","unstructured":"Ette EI, Kelman AW, Howie CA, Whiting B. Analysis of animal pharmacokinetic data: performance of the one point per animal design. J Pharmacokinet Biopharm. 1995;23:551\u201366.","journal-title":"J Pharmacokinet Biopharm"},{"key":"115_CR22","first-page":"4209","volume":"6","author":"ME Scheulen","year":"2000","unstructured":"Scheulen ME, Hilger RA, Oberhoff C, Casper J, Freund M, Josten KM, et al. Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Clin Cancer Res. 2000;6:4209\u201316.","journal-title":"Clin Cancer Res"},{"key":"115_CR23","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1002\/jps.24662","volume":"104","author":"M Roma\u0144ski","year":"2015","unstructured":"Roma\u0144ski M, Urbaniak B, Kokot Z, G\u0142\u00f3wka FK. Activation of prodrug treosulfan at pH 7.4 and 37\u00b0C accompanied by hydrolysis of its active epoxides: kinetic studies with clinical relevance. J Pharm Sci. 2015;104:4433\u201342.","journal-title":"J Pharm Sci"},{"key":"115_CR24","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/j.xphs.2017.03.018","volume":"106","author":"M Roma\u0144ski","year":"2017","unstructured":"Roma\u0144ski M, Ratajczak W, G\u0142\u00f3wka F. Kinetic and mechanistic study of the pH-dependent activation (epoxidation) of prodrug treosulfan including the reaction inhibition in a borate buffer. J Pharm Sci. 2017;106:1917\u201322.","journal-title":"J Pharm Sci"},{"key":"115_CR25","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1098\/rsfs.2010.0025","volume":"1","author":"P Orlowski","year":"2011","unstructured":"Orlowski P, Chappell M, Park CS, Grau V, Payne S. Modelling of pH dynamics in brain cells after stroke. Interface Focus. 2011;1:408\u201316.","journal-title":"Interface Focus"},{"key":"115_CR26","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/sj.bmt.1704784","volume":"35","author":"DW Beelen","year":"2005","unstructured":"Beelen DW, Trenschel R, Casper J, Freund M, Hilger RA, Scheulen ME, et al. Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplant. 2005;35:233\u201341.","journal-title":"Bone Marrow Transplant"},{"issue":"Suppl 2","key":"115_CR27","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1038\/bmt.2008.287","volume":"42","author":"FK G\u0142\u00f3wka","year":"2008","unstructured":"G\u0142\u00f3wka FK, Kara\u017aniewicz-\u0141ada M, Grund G, Wr\u00f3bel T, Wachowiak J. Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCT. Bone Marrow Transplant. 2008;42(Suppl 2):S67\u201370.","journal-title":"Bone Marrow Transplant"},{"key":"115_CR28","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s002800050791","volume":"42","author":"RA Hilger","year":"1998","unstructured":"Hilger RA, Harstrick A, Eberhardt W, Oberhoff C, Skorzec M, Baumgart J, et al. Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors. Cancer Chemother Pharmacol. 1998;42:99\u2013104.","journal-title":"Cancer Chemother Pharmacol"},{"key":"115_CR29","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/ALN.0b013e318164cf9e","volume":"108","author":"E Bostr\u00f6m","year":"2008","unstructured":"Bostr\u00f6m E, Hammarlund-Udenaes M, Simonsson USH. Blood-brain barrier transport helps to explain discrepancies in in vivo potency between oxycodone and morphine. Anesthesiology. 2008;108:495\u2013505.","journal-title":"Anesthesiology"},{"key":"115_CR30","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1124\/jpet.104.079319","volume":"313","author":"X Liu","year":"2005","unstructured":"Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X, et al. Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding. J Pharmacol Exp Ther. 2005;313:1254\u201362.","journal-title":"J Pharmacol Exp Ther"},{"key":"115_CR31","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","volume":"11","author":"RM Savic","year":"2009","unstructured":"Savic RM, Karlsson MO. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J. 2009;11:558\u201369.","journal-title":"AAPS J"},{"key":"115_CR32","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00228-017-2344-x","volume":"74","author":"D Danielak","year":"2018","unstructured":"Danielak D, Twardosz J, Kasprzyk A, Wachowiak J, Ka\u0142wak K, G\u0142\u00f3wka F. Population pharmacokinetics of treosulfan and development of a limited sampling strategy in children prior to hematopoietic stem cell transplantation. Eur J Clin Pharmacol. 2018;74:79\u201389.","journal-title":"Eur J Clin Pharmacol"},{"key":"115_CR33","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/bjh.14960","volume":"179","author":"MYEC van der Stoep","year":"2017","unstructured":"van der Stoep MYEC, Bertaina A, Ten Brink MH, Bredius RG, Smiers FJ, Wanders DCM, et al. High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric HSCT: a prospective multicentre study. Br J Haematol. 2017;179:772\u201380.","journal-title":"Br J Haematol"},{"key":"115_CR34","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/cpt.988","volume":"104","author":"E Mohanan","year":"2018","unstructured":"Mohanan E, Panetta JC, Lakshmi KM, Edison ES, Korula A, NA F, et al. Pharmacokinetics and pharmacodynamics of treosulfan in patients with thalassemia major undergoing allogeneic hematopoietic stem cell transplantation. Clin Pharmacol Ther. 2018;104:575\u201383.","journal-title":"Clin Pharmacol Ther"},{"key":"115_CR35","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/FTD.0000000000000047","volume":"36","author":"MH Ten Brink","year":"2014","unstructured":"Ten Brink MH, Ackaert O, Zwaveling J, Bredius RGM, Smiers FJ, den Hartigh J, et al. Pharmacokinetics of treosulfan in pediatric patients undergoing hematopoietic stem cell transplantation. Ther Drug Monit. 2014;36:465\u201372.","journal-title":"Ther Drug Monit"},{"key":"115_CR36","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1124\/jpet.102.033878","volume":"302","author":"Y Kato","year":"2002","unstructured":"Kato Y, Kuge K, Kusuhara H, Meier PJ, Sugiyama Y. Gender difference in the urinary excretion of organic anions in rats. J Pharmacol Exp Ther. 2002;302:483\u20139.","journal-title":"J Pharmacol Exp Ther"},{"key":"115_CR37","doi-asserted-by":"crossref","first-page":"F361","DOI":"10.1152\/ajprenal.00207.2006","volume":"292","author":"M Ljubojevi\u0107","year":"2007","unstructured":"Ljubojevi\u0107 M, Balen D, Breljak D, Kusan M, Anzai N, Bahn A, et al. Renal expression of organic anion transporter OAT2 in rats and mice is regulated by sex hormones. Am J Physiol Renal Physiol. 2007;292:F361\u2013372.","journal-title":"Am J Physiol Renal Physiol"},{"key":"115_CR38","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.taap.2014.08.020","volume":"280","author":"W-Y Hou","year":"2014","unstructured":"Hou W-Y, Xu S-F, Zhu Q-N, Lu Y-F, Cheng X-G, Liu J. Age- and sex-related differences of organic anion-transporting polypeptide gene expression in livers of rats. Toxicol Appl Pharmacol. 2014;280:370\u20137.","journal-title":"Toxicol Appl Pharmacol"},{"key":"115_CR39","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/CAD.0000000000000238","volume":"26","author":"U Linz","year":"2015","unstructured":"Linz U, Hupert M, Santiago-Sch\u00fcbel B, Wien S, Stab J, Wagner S. Transport of treosulfan and temozolomide across an in-vitro blood-brain barrier model. Anticancer Drugs. 2015;26:728\u201336.","journal-title":"Anticancer Drugs"},{"key":"115_CR40","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jchromb.2013.02.012","volume":"923\u2013924","author":"FK G\u0142\u00f3wka","year":"2013","unstructured":"G\u0142\u00f3wka FK, Roma\u0144ski M, Siemi\u0105tkowska A. Determination of partition coefficients n-octanol\/water for treosulfan and its epoxy-transformers: an example of a negative correlation between lipophilicity of unionized compounds and their retention in reversed-phase chromatography. J Chromatogr B. 2013;923\u2013924:92\u20137.","journal-title":"J Chromatogr B"},{"key":"115_CR41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0006-8993(88)90577-X","volume":"462","author":"QR Smith","year":"1988","unstructured":"Smith QR, Ziylan YZ, Robinson PJ, Rapoport SI. Kinetics and distribution volumes for tracers of different sizes in the brain plasma space. Brain Res. 1988;462:1\u20139.","journal-title":"Brain Res"},{"key":"115_CR42","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1471-2202-9-67","volume":"9","author":"W Shang","year":"2008","unstructured":"Shang W, Liu W-H, Zhao X-H, Sun Q-J, Bi J-Z, Chi Z-F. Expressions of glutathione S-transferase alpha, mu, and pi in brains of medically intractable epileptic patients. BMC Neurosci. 2008;9:67.","journal-title":"BMC Neurosci"},{"key":"115_CR43","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1096\/fj.04-3128fje","volume":"19","author":"KW Sellers","year":"2005","unstructured":"Sellers KW, Sun C, Diez-Freire C, Waki H, Morisseau C, Falck JR, et al. Novel mechanism of brain soluble epoxide hydrolase-mediated blood pressure regulation in the spontaneously hypertensive rat. FASEB. 2005;19:626\u20138.","journal-title":"FASEB"},{"key":"115_CR44","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1369\/jhc.2008.950659","volume":"56","author":"P Sura","year":"2008","unstructured":"Sura P, Sura R, EnayetAllah AE, Grant DF. Distribution and expression of soluble epoxide hydrolase in human brain. J Histochem Cytochem. 2008;56:551\u20139.","journal-title":"J Histochem Cytochem"},{"key":"115_CR45","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/clpt.2013.161","volume":"94","author":"DF Carr","year":"2013","unstructured":"Carr DF, O\u2019Meara H, Jorgensen AL, Campbell J, Hobbs M, McCann G, et al. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink. Clin Pharmacol Ther. 2013;94:695\u2013701.","journal-title":"Clin Pharmacol Ther"},{"key":"115_CR46","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1002\/pbc.25191","volume":"61","author":"H-N Zhang","year":"2014","unstructured":"Zhang H-N, He X-L, Wang C, Wang Y, Chen Y-J, Li J-X, et al. Impact of SLCO1B1 521T > C variant on leucovorin rescue and risk of relapse in childhood acute lymphoblastic leukemia treated with high-dose methotrexate. Pediatr Blood Cancer. 2014;61:2203\u20137.","journal-title":"Pediatr Blood Cancer"},{"key":"115_CR47","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1007\/s00415-006-0459-6","volume":"254","author":"H Wiendl","year":"2007","unstructured":"Wiendl H, Kieseier BC, Weissert R, Mylius HA, Pichlmeier U, Hartung H-P, et al. Treatment of active secondary progressive multiple sclerosis with treosulfan. J Neurol. 2007;254:884\u20139.","journal-title":"J Neurol"}],"updated-by":[{"DOI":"10.1007\/s43440-020-00144-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T00:00:00Z","timestamp":1597190400000}}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-020-00115-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-020-00115-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-020-00115-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,29]],"date-time":"2021-05-29T23:30:21Z","timestamp":1622331021000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-020-00115-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,30]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["115"],"URL":"https:\/\/doi.org\/10.1007\/s43440-020-00115-0","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s43440-020-00144-9","asserted-by":"object"}]},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,30]]},"assertion":[{"value":"4 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2020","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this article, published on 30 May 2020 contained a mistake.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}